Startup profile · funding coverage
Aptadir Therapeutics funding, valuation and investors
RNA therapeutics company developing demethylating medicines; raised a €40 million seed round.
Keep track of Aptadir Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
€40M ($45M) · September 29, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$45M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Milan, Italy
Investors in latest funding
Lead: 4BIO Capital
Other: EXTEND
Overview
Aptadir Therapeutics is developing RNA inhibitor-based medicines intended to reverse abnormal DNA methylation in genetic disease. On September 29, 2026 the Milan-based company announced the closing of a €40 million ($45 million) seed round led by 4BIO Capital with follow-on participation from EXTEND.
Why Aptadir Therapeutics is interesting
An unusually large biotech seed round with multi-institution science and clear primary-source disclosure.
Key facts
- Sep 29, 2026: €40M seed
- 4BIO Capital led the round
Funding history (newest first)
Seed
2026-09-29 €40M ($45M)- 4BIO Capital (lead)
- EXTEND (participant)
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.